NasdaqCM USD

Nuwellis, Inc. (NUWE)

5.68 -0.10 (-1.73%)

At close: October 30 at 4:00:00 PM EDT

5.41 -0.27 (-4.75%)

Pre-Market: 4:20:35 AM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

GlobeNewswire 5d ago

NUWE
-1.73%
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

GlobeNewswire 24d ago

NUWE
-1.73%
Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

GlobeNewswire 1mo ago

NUWE
-1.73%
Nuwellis Reports 31 Aquadex Console Sales in 2026, Expanding Recurring Revenue Opportunity

InvestorsHub 1mo ago

NUWE
-1.73%
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

GlobeNewswire 1mo ago

NUWE
-1.73%
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

GlobeNewswire 1mo ago

NUWE
-1.73%
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

GlobeNewswire 2mo ago

NUWE
-1.73%
Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...

GuruFocus.com 2mo ago

NUWE
-1.73%
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

GlobeNewswire 2mo ago

NUWE
-1.73%
Nuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User Interface

GlobeNewswire 2mo ago

NUWE
-1.73%
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire 3mo ago

NUWE
-1.73%
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

GlobeNewswire 3mo ago

NUWE
-1.73%

Performance Overview

Return	NUWE	S&P 500 (^GSPC)
YTD	-90.67%	+10.73%
1-Year	-95.73%	+11.11%
3-Year	-99.99%	+81.91%

U.S. markets open in 2h 50m

Nuwellis, Inc. (NUWE)

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

Nuwellis Reports 31 Aquadex Console Sales in 2026, Expanding Recurring Revenue Opportunity

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User Interface

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy